Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
Phase 1/2
51
about 4.3 years
18+
1 site in TX
What this study is about
This trial is testing a treatment called TROP2-CAR-NK given directly into the abdominal cavity to people with ovarian cancer that hasn't responded to other treatments or has become resistant. The goal is to find the best dose of this treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cyclophosphamide
- 2.Take Fludarabine
- 3.Take TROP2-CAR-NK
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Oncology